Kevin J. Freise - Concepedia

Author

Kevin J. Freise

Also Known As

, K Freise, K J Freise, K. Freise, K. J. FREISE, K. J. Freise, K.J. Freise, Kevin Freise, Kevin J Freise, Kevin J. Freise

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

AbbVie (United States)Ain Shams University Mayo Clinic in Arizona University of Iowa Duke University

About

Kevin J. Freise is an author at AbbVie (United States) specializing in medicine, hematology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	905
2	Health Sciences	12	12	754
3	Education	1	1	18
4	Public Health	1	1	30
5	Anatomy	1	1	14

Kevin J. Freise

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial Shaji Kumar, Simon J. Harrison, Michèle Cavo, The Lancet Oncology Hematological MalignancyOncologyHematologyMyeloid NeoplasiaPharmacotherapy	2020	390
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM Philippe Moreau, Asher Chanan‐Khan, Andrew W. Roberts, Blood	2017	271
First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors Sarina A. Piha‐Paul, Jasgit C. Sachdev, Minal Barve, Clinical Cancer Research	2019	156
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma Anita D’Souza, Nina Shah, Cesar Rodriguez, Journal of Clinical Oncology	2022	115
Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis Aksana K. Jones, Kevin J. Freise, Suresh Agarwal, The AAPS Journal Hematological MalignancyLymphoid NeoplasiaOncologyLymphoma PatientsVenetoclax Pharmacokinetics	2016	99
Effect of Low‐ and High‐Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First‐in‐Class BCL‐2 Inhibitor Ahmed Hamed Salem, Suresh Agarwal, Martin Dunbar, The Journal of Clinical Pharmacology	2016	88
Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model Kevin J. Freise, Mohamad Shebley, Ahmed Hamed Salem The Journal of Clinical Pharmacology	2017	77
Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia Kevin J. Freise, Aksana K. Jones, Doerthe Eckert, Clinical Pharmacokinetics Hematological MalignancyLymphoid NeoplasiaMedicineHematologyImmunology	2016	61
Instrumental evaluation of pH effects on ability of pork chops to bloom M.S. BREWER, Jan Novakofski, Kevin J. Freise Meat Science NutritionFood AnalysisPh EffectsInstrumental EvaluationAgricultural Economics	2005	50
Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers Ahmed Hamed Salem, Beibei Hu, Kevin J. Freise, Clinical Drug Investigation ThrombosisHealth SciencesMedicineHealthy VolunteersHematology	2016	50

Page 1